166 related articles for article (PubMed ID: 28628770)
21. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
22. ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
Liu RT; Zhang P; Yang CL; Pang Y; Zhang M; Zhang N; Yue LT; Li XL; Li H; Duan RS
J Neuroimmunol; 2017 Oct; 311():71-78. PubMed ID: 28844501
[TBL] [Abstract][Full Text] [Related]
23. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
Claes DJ; Yin H; Goebel J
Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
27. ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
Neumaier HL; Harel S; Klingel K; Kaya Z; Heuser A; Kespohl M; Beling A
Cells; 2020 Apr; 9(5):. PubMed ID: 32354159
[No Abstract] [Full Text] [Related]
28. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
30. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
[No Abstract] [Full Text] [Related]
33. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.
Vogelbacher R; Meister S; Gückel E; Starke C; Wittmann S; Stief A; Voll R; Daniel C; Hugo C
Nephrol Dial Transplant; 2010 Nov; 25(11):3764-73. PubMed ID: 20466656
[TBL] [Abstract][Full Text] [Related]
34. HLA desensitization with bortezomib in a highly sensitized pediatric patient.
May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA
Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602
[TBL] [Abstract][Full Text] [Related]
35. Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.
Al-Homsi AS; Lai Z; Roy TS; Kouttab N
Transpl Immunol; 2013 Dec; 29(1-4):1-6. PubMed ID: 24103732
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
38. Different roles of bortezomib and ONX 0914 in acute kidney injury.
Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
Int Immunopharmacol; 2020 Mar; 82():106259. PubMed ID: 32143000
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
Perry DK; Burns JM; Pollinger HS; Amiot BP; Gloor JM; Gores GJ; Stegall MD
Am J Transplant; 2009 Jan; 9(1):201-9. PubMed ID: 18976291
[TBL] [Abstract][Full Text] [Related]
40. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
